Cyfuse Biomedical K.K. (TYO:4892)

Market Cap	6.08B -40.2%
Revenue (ttm)	230.00M +325.9%
Net Income	-763.00M
EPS	-86.69
Shares Out	9.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,000
Average Volume	84,115
Open	596.00
Previous Close	605.00
Day's Range	596.00 - 615.00
52-Week Range	516.00 - 1,068.00
Beta	1.53
RSI	46.63
Earnings Date	Feb 13, 2026

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine-related products in Japan and the United States. The company develops cellular products for the regenerative medicine and cellular therapy fields; and undertakes various contracts for research cell products. It also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from ce...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4892

Financial Performance

In 2025, Cyfuse Biomedical K.K.'s revenue was 230.00 million, an increase of 325.93% compared to the previous year's 54.00 million. Losses were -763.00 million, -12.50% less than in 2024.